170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2022-10, Vol.21, p.S99-S100
Main Authors: Griese, M., Tullis, E., Chilvers, M., Fabrizzi, B., Jain, R., Legg, J., Mall, M., McKone, E., Polineni, D., Poplawska, K., Robinson, P., Taylor-Cousar, J., Ahluwalia, N., Doolittle, C., Jennings, M., Moskowitz, S., Prieto-Centurion, V., Tan, Y.V., Tian, S., Vinarsky, V., Weinstock, T., Xuan, F., Ramsey, B., Daines, C.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1569-1993
1873-5010
DOI:10.1016/S1569-1993(22)00861-X